Subclinical hypothyroidism after pre-eclampsia

BMJ (Online)

Volumn 339, Issue 7734, 2009, Pages 1323-

  North, Robyn A ^a   Taylor, Robert N ^b  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENIC FACTOR; BEVACIZUMAB; FIBROBLAST GROWTH FACTOR RECEPTOR 1; PLACENTAL GROWTH FACTOR; SUNITINIB; THYROID PEROXIDASE ANTIBODY; THYROTROPIN; THYROXINE; VASCULOTROPIN;

ADULT; BLOOD VESSEL INJURY; CARDIOVASCULAR RISK; CLINICAL ASSESSMENT; CONTROLLED STUDY; CORRELATION ANALYSIS; EDITORIAL; FEMALE; FOLLOW UP; HIGH RISK PATIENT; HORMONE BLOOD LEVEL; HUMAN; HYPOTHYROIDISM; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MATERNAL HYPERTENSION; PREECLAMPSIA; PRIORITY JOURNAL; PROTEINURIA; RISK ASSESSMENT; RISK FACTOR; SOLUTIO PLACENTAE; THIRD TRIMESTER PREGNANCY; THYROID FUNCTION;

FEMALE; HUMANS; HYPOTHYROIDISM; PRE-ECLAMPSIA; PREGNANCY; RISK FACTORS; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1;

EID: 72449212432     PISSN: None     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.b5183     Document Type: Editorial

References (12)

1. Biondi B, Cooper DS. The clinical significance of subclinical thyroid dysfunction. Endocr Rev 2008;29:76-131.[Abstract/Free Full Text] (Pubitemid 351252748)
2. Levine RJ, Vatten LJ, Horowitz GL, Qian C, Romundstad PR, Yu KF, et al. Pre-eclampsia, soluble fms-like tyrosine kinase 1, and the risk of reduced thyroid function: nested case-control and population based study. BMJ 2009;339:b4336.[Abstract/Free Full Text]
3. Lao TT, Chin RK, Swaminathan R, Lam YM. Maternal thyroid hormones and outcome of pre-eclamptic pregnancies. Br J Obstet Gynaecol 1990;97:71-74[Web of Science][Medline] (Pubitemid 20136132)
4. Cleary-Goldman J, Malone FD, Lambert-Messerlian G, Sullivan L, Canick J, Porter TF, et al. Maternal thyroid hypofunction and pregnancy outcome. Obstet Gynecol 2008;112:85-92.[CrossRef][Web of Science][Medline]
5. Levine RJ, Maynard SE, Qian C, Lim KH, England LJ, Yu KF, et al. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 2004;350:672-683[Abstract/Free Full Text] (Pubitemid 38364626)
6. Kamba T, Tam BY, Hashizume H, Haskell A, Sennino B, Mancuso MR, et al. VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature. Am J Physiol Heart Circ Physiol 2006;290:H560-76.[Abstract/ Free Full Text]
7. Feldman DR, Baum MS, Ginsberg MS, Hassoun H, Flombaum CD, Velasco S, et al. Phase I trial of bevacizumab plus escalated doses of sunitinib in patients with metastatic renal cell carcinoma. J Clin Oncol 2009;27:1432-1439[Abstract/ Free Full Text]
8. Redman CW, Sargent IL. Latest advances in understanding preeclampsia. Science 2005;308:1592-1594 [Abstract/Free Full Text]
9. Vikse BE, Irgens LM, Leivestad T, Skjaerven R, Iversen BM. Preeclampsia and the risk of end-stage renal disease. N Engl J Med 2008;359:800-809[Abstract/ Free Full Text]
10. Bellamy L, Casas JP, Hingorani AD, Williams DJ. Pre-eclampsia and risk of cardiovascular disease and cancer in later life: systematic review and meta-analysis. BMJ 2007;335:974.[Abstract/Free Full Text] (Pubitemid 350144670)
11. Magnussen EB, Vatten LJ, Lund-Nilsen TI, Salvesen KA, Davey Smith G, Romundstad PR. Prepregnancy cardiovascular risk factors as predictors of pre-eclampsia: population based cohort study. BMJ 2007;335:978.[Abstract/Free Full Text]
12. Ray JG, Vermeulen MJ, Schull MJ, Redelmeier DA. Cardiovascular health after maternal placental syndromes (CHAMPS): population-based retrospective cohort study. Lancet 2005;366:1797-1803 [CrossRef][Web of Science][Medline]